
Scott Edmondson leaves AstraZeneca, starts new chapter at Nimbus; With IPO filed, Taysha pulls together an AveXis-heavy team
→ Nimbus Therapeutics, which identified 4 new targets – AMPKβ2, CTPS1, Cbl-b and WRN – in their drug discovery efforts, has reeled in a big fish with Big Pharma vet Scott Edmondson now a part of the mix as SVP, head of chemistry. Edmondson had been AstraZeneca’s director and head of Boston oncology chemistry for almost 4 years.
From 1998-2016, Edmondson was at Merck and worked his way up to director of discovery chemistry. While at the pharma giant, he discovered vibegron for patients with overactive bladder, a drug that Urovant would pick up in 2017. Urovant filed for an NDA for vibegron at the FDA, which the agency accepted for review in March.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.